DVA.NYSEDavita INC

Form 4: DaVita CFO Joel Ackerman Reports Stock Transactions

Sentiment:

SEC Form 4


CFO and Treasurer of DaVita Inc., Joel Ackerman, reports acquisition and disposal of common stock and stock appreciation rights on March 15, 2025.

Summary

  • On March 15, 2025, Joel Ackerman, CFO and Treasurer of DaVita Inc., reported transactions involving the company's common stock and stock appreciation rights.
  • Ackerman acquired 5,995 shares of common stock at $0.
  • He disposed of 3,093 shares at $143.45 and 3,331 shares at $143.45 to cover tax withholding obligations related to vesting performance stock units.
  • Ackerman also acquired 16,597 stock appreciation rights with an exercise price of $143.45, exercisable starting March 15, 2028, and expiring March 15, 2030.
  • Following these transactions, Ackerman directly owns 141,640 shares of common stock and 16,597 stock appreciation rights.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports routine stock transactions related to executive compensation and tax obligations. The acquisition of stock appreciation rights could be seen as slightly positive, indicating confidence in the company's future performance.

Positives

  • The acquisition of stock appreciation rights suggests a positive outlook by the CFO on the company's future performance.

Future Outlook

The vesting schedule of the restricted stock units and stock appreciation rights (50% on March 15, 2028, and 50% on March 15, 2029) suggests a long-term incentive plan for the CFO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the actions of company executives and directors.

Comparison to Industry Standards

  • Comparing DaVita's executive compensation and equity grants to peers like Fresenius Medical Care and Baxter International would provide context on whether these grants are standard.
  • Analyzing the vesting schedules and performance criteria against industry benchmarks can reveal if DaVita's incentives are aligned with long-term shareholder value creation.

Stakeholder Impact

  • The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.
  • Transparency in insider transactions helps maintain investor confidence.

Key Dates

DateDescription
03/15/2021Date of grant of performance stock units relating to the 2024 performance period.
03/15/2022Date of grant of performance stock units relating to the 2024 performance period.
03/15/2025Date of reported transactions: acquisition/disposal of common stock and acquisition of stock appreciation rights.
03/15/2028Date when 50% of the restricted stock units and stock appreciation rights are scheduled to vest.
03/15/2029Date when the remaining 50% of the restricted stock units and stock appreciation rights are scheduled to vest.
03/15/2030Expiration date of the stock appreciation rights.
03/18/2025Date of signature by Attorney-in-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.